At Aphex Pharma Solutions, we leverage cutting-edge in silico technologies to transform traditional drug discovery. Our computational biology services are designed to:
- Reduce R&D costs
- Accelerate discovery timelines
- Improve clinical success probability
The Challenge
Bringing a new drug to market today can cost over $1 billion and take more than a decade. Despite this enormous investment, many approved therapies benefit only a limited subset of the population. These challenges along with declining R&D productivity and the rise of imprecision medicine highlight an urgent need for smarter, faster, and more cost-effective approaches to drug development.
The Game Changer
Testing millions of molecules in the wet lab is impractical and expensive. Our computational pipeline helps you:
- Prioritize only the best candidates
- Avoid wasted effort on non-viable compounds
- Reach experimental validation faster on cell lines, animal models, and eventually human trials
Basic Steps in Computer-Aided Drug Designing
How Do We Work
We combine biology, chemistry, AI, and high-performance computing to:
- Screen millions of compounds
- Perform structural optimization
- Predict drug-target interactions
- Optimize lead candidates for efficacy, selectivity, and safety
Disease Targets
We use systems biology and omics data integration to uncover and validate novel disease targets across a wide range of conditions:
From target identification to lead optimization, our platform accelerates discovery and delivers innovative, non-toxic, patentable small molecules.
Deliverables
Targeted Disease-Specific Libraries
Curated compound libraries specifically designed for your target disease area
Non-Toxic ADMET-Filtered Hits
Pre-screened compounds with optimized absorption, distribution, metabolism, excretion, and toxicity profiles
Novel Compounds for Validation
Target-specific innovative compounds ready for experimental validation
Difficult Target Support
Specialized solutions for challenging targets like protein–protein interactions
Unique Chemical Structures
Proprietary molecules with strong binding potential and minimal redundancy
Ready to Transform Your Drug Discovery?
Contact us at drugdiscovery@aphexpharma.com